Status:
COMPLETED
Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -
Lead Sponsor:
Pfizer
Conditions:
Pneumonia
Lung Abscess
Eligibility:
All Genders
15-99 years
Brief Summary
The purpose of the survey is to study the followings under practical use, regarding the safety and effectiveness in high-dose administration (exceeding 6 g per day) of UNASYN-S and UNASYN-S KIT for in...
Detailed Description
Implemented as a Special Investigation by a central registration system. Secondary data collection. Safety and effectiveness of UNASYN-S under Japanese medical practice.
Eligibility Criteria
Inclusion
- Patients with the following disease who received high doses of UNASYN (exceeding 6 g per day) from the first dosing date or the second dosing date. 1) Pneumonia, 2) Lung Abscess, 3) Peritonitis
- Patients aged 15 years or more
Exclusion
- Patients with the following disease who received high doses of UNASYN (less than 6 g per day) from the first dosing date or the second dosing date. 1) Pneumonia, 2) Lung Abscess, 3) Peritonitis
- Patients aged less than 15 years.
Key Trial Info
Start Date :
March 12 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 27 2016
Estimated Enrollment :
982 Patients enrolled
Trial Details
Trial ID
NCT01793688
Start Date
March 12 2013
End Date
January 27 2016
Last Update
April 26 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.